OR WAIT 15 SECS
© 2021 MJH Life Sciences and Pharmaceutical Technology. All rights reserved.
© 2021 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
Pharmaceutical Technology Europe
September 01, 2010
No one can deny the power of social media; it has revolutionised communication and empowered consumers, creating a medium that allows the free flow of information with no authority to control it.
A Strengths, Weaknesses, Opportunities and Threats analysis of the biosimilars market is given.
Despite the poor economic climate, large-scale mergers and acquisitions in the pharmaceutical industry struck back with a vengeance in 2009.
In an increasingly competitive landscape, outsourcing providers are under mounting pressure to get their name out there and secure new and repeat business.
The economic crisis has affected outsourcing providers in several ways.
India has evolved from a low-cost region to an area with extensive technical capability and high quality standards.
In light of the impressive size and predicted growth of the market, there has been a rising interest in the development of biosimilars.
The manufacture of high potency active pharmaceutical ingredients (HPAPIs) is on the rise with R&D projects showing a continuing interest in these products.
Pharma struggling with social media; Opportunities in the OTC market
Industry experts discuss the merits of continuous processing technology and explain why pharma manufacturers should realize the benefits these technologies offer.
Utilizing integrated active radio frequency identification (RFID) and real-time asset management systems can yield commercial and compliance benefits.
When assessing the competencies of an outsourcing service provider, sponsor companies must pay a great deal of attention to the cGMP compliance level of the provider.
Many hurdles lie between a biosimilar and success on the market. In particular, there are three main questions that companies will be asking themselves.
A case study describing how Lean can drive the creation of an improved culture within pharmaceutical companies.
Both biosimilar and generic drugs have an abbreviated approval process; however, the clinical trial requirements differ enormously.
How to find the right partner in Asia–Pacific is a very complex question and there is no uniform answer.
One particularly crucial parameter for nasal sprays is the size of the droplets produced during actuation, which can potentially impact bioavailability.
Last year, the global market for biological products exceeded $125 billion, accounting for 17% of the total market for pharma/biopharma products.